NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 123 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.33 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,683,492 | -58.7% | 1,573,357 | 0.0% | 0.38% | -50.3% |
| Q2 2023 | $4,074,995 | -48.4% | 1,573,357 | 0.0% | 0.75% | -48.6% |
| Q1 2023 | $7,898,252 | 0.0% | 1,573,357 | 0.0% | 1.47% | +42.5% |
| Q4 2022 | $7,898,252 | -61.6% | 1,573,357 | 0.0% | 1.03% | -64.8% |
| Q3 2022 | $20,580,000 | +2.0% | 1,573,357 | 0.0% | 2.93% | +35.7% |
| Q2 2022 | $20,170,000 | -15.9% | 1,573,357 | 0.0% | 2.16% | +20.6% |
| Q1 2022 | $23,994,000 | -13.9% | 1,573,357 | 0.0% | 1.79% | +12.7% |
| Q4 2021 | $27,864,000 | -15.7% | 1,573,357 | 0.0% | 1.59% | -25.9% |
| Q3 2021 | $33,072,000 | – | 1,573,357 | – | 2.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $79,175,000 | 44.14% |
| Ponoi II Management, LLC | 1,298,908 | $27,303,000 | 40.46% |
| Column Group LLC | 15,396,116 | $323,626,000 | 36.81% |
| Ponoi Management, LLC | 1,298,908 | $27,303,000 | 24.24% |
| Euclidean Capital LLC | 832,274 | $17,494,000 | 8.50% |
| StepStone Group LP | 1,573,357 | $33,072,000 | 2.14% |
| Octagon Capital Advisors LP | 200,000 | $4,204,000 | 1.04% |
| Redmile Group, LLC | 2,505,118 | $52,658,000 | 0.92% |
| BVF INC/IL | 955,000 | $20,074,000 | 0.78% |
| Boxer Capital, LLC | 500,000 | $10,510,000 | 0.37% |